Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis.
Pediatr Allergy Immunol
; 34(7): e13982, 2023 07.
Article
in En
| MEDLINE
| ID: mdl-37492920
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Urticaria
/
Anti-Allergic Agents
/
Chronic Urticaria
Type of study:
Clinical_trials
/
Prognostic_studies
Aspects:
Patient_preference
Limits:
Adolescent
/
Adult
/
Child
/
Humans
Language:
En
Journal:
Pediatr Allergy Immunol
Journal subject:
ALERGIA E IMUNOLOGIA
/
PEDIATRIA
Year:
2023
Document type:
Article
Affiliation country:
Germany